Victor Murray, MSW, of the Camden Coalition, delves into the evolving role of social workers, focusing on advocacy, systems ...

Patients reported that side effects often impacted their quality of life (QOL). However, most patients said their treatment ...

Abstracts published ahead of the 2025 American Society of Clinical Oncology Annual Meeting found persistent ovarian cancer ...

Cathy Eng, MD, FACP, FASCO, Vanderbilt-Ingram Cancer Center, speaks about the clinical and operational priorities that ...

Pediatric research explored environmental interventions for bronchiolitis, heart function in children born preterm, and a ...

Jonathan Strober, MD, explains the initial presentation of myasthenia gravis in a pediatric patient population and why initial diagnosis for these patients can be challenging.

Panelists discuss how proactive patient education, lipid-lowering interventions, and monitoring tools can help patients stay ...

Panelists discuss how step-therapy for immunoglobulin A (IgA) nephropathy is evolving toward a more personalized approach, ...

Recent research reveals COVID-19 significantly increases long-term kidney dysfunction risk compared with influenza, ...

Congress is unlikely to codify the recent executive order to lower drug pricing as other US officials negotiate new prices, John Barkett, MBA, of Berkeley Research Group, explains.

Panelists discuss how lorlatinib’s unique adverse event (AE) profile, including cognitive effects, hypercholesterolemia, and peripheral neuropathy, impacts treatment selection and patient management.

The repeal of the federal rule could leave those with mental health and substance use disorders at risk of losing coverage for their treatment.